A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation

• No prior systemic treatment in the metastatic setting

• ECOG Performance status 0-1

• Adequate organ function

Exclusion Criteria:

• Prior treatment with any KRAS inhibitor

• Chronic or current active infection requiring systemic treatment within 1 week priorto the first dose of study drug

• Known active CNS metastases

Other protocol-defined Inclusion/Exclusion Criteria may apply.